Scope
This focused NICE NG115 summary covers COPD diagnosis, inhaled treatment escalation, rehabilitation, oxygen assessment and acute exacerbation care. The pathway requires spirometry interpreted with symptoms, checks for other causes of deterioration and distinguishes stable management from an acute respiratory emergency. Its treatment rules belong to this NICE edition and should not be silently combined with a different guideline’s escalation scheme.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm obstruction in the clinical context
- Suspect COPD in people over 35 with a relevant risk exposure and exertional breathlessness, chronic cough, regular sputum, recurrent winter bronchitis or wheeze. Confirm with post-bronchodilator spirometry; chest pain or haemoptysis should prompt consideration of another diagnosis. [1]
- Interpret spirometry alongside symptoms: consider alternatives in an older person with FEV1/FVC below 0.7 but no typical symptoms, and consider COPD in a symptomatic younger person even when the ratio exceeds 0.7. [1]
- At initial evaluation, obtain a chest radiograph, blood count and BMI as well as spirometry. Consider further testing for disproportionate symptoms or an alternative cause; early onset, little smoking or a family history may warrant alpha-1 antitrypsin assessment. [1]
- Assess symptoms, exacerbation history, exercise capacity, hypoxia, comorbidity and frailty rather than relying on one lung-function number. Reconsider the diagnosis when treatment response is unexpectedly marked. [1]
Optimize basic care before escalating inhalers
- At every opportunity, offer help to stop smoking, with cessation treatment and support. Use short-acting bronchodilators as needed for initial relief of breathlessness and exercise limitation. [1]
- For confirmed COPD without asthmatic or steroid-responsive features, offer LAMA plus LABA if breathlessness or exacerbations persist despite a short-acting bronchodilator, optimized non-drug care and vaccinations, and tobacco treatment when applicable. [1]
- With confirmed COPD and asthmatic or steroid-responsive features, consider LABA plus inhaled corticosteroid after the same basic measures. Discuss ICS adverse effects, including pneumonia; oral steroid reversibility testing should not determine ICS selection. [1]
- Before triple therapy, check that smoking treatment and non-drug care are optimized and that symptoms or acute deteriorations are truly due to COPD rather than another physical or mental-health condition. [1]
- On LABA plus ICS, offer triple LAMA/LABA/ICS for persistent symptoms impairing quality of life, a hospitalization-requiring exacerbation, or 2 moderate exacerbations in a year. On LAMA plus LABA, consider triple therapy for the same exacerbation thresholds. [1]
- For quality-of-life-limiting symptoms on LAMA plus LABA, consider a 3-month triple-therapy trial. Continue only if symptoms improve; otherwise return to LAMA plus LABA. Document why ICS is continued and review at least annually. [1]
- Choose inhalers according to benefit, preference and ability to use them, exacerbation prevention, adverse effects and cost. Minimize device variety and prescribe devices in which the person has been trained. [1]
Address function and assess oxygen safely
- Offer pulmonary rehabilitation for functionally limiting COPD, usually MRC dyspnoea grade 3 or higher, including appropriate people after hospitalization. The NICE pathway excludes those unable to walk, with unstable angina or a recent MI; programmes combine exercise, education and nutritional, psychological and behavioural support. [1]
- Assess oxygen need in marked obstruction, cyanosis, polycythaemia, oedema or resting air saturation at most 92%. Use arterial blood gases on 2 occasions at least 3 weeks apart when COPD is stable and medical management optimized; a single oximeter reading is insufficient for long-term prescription. [1]
- Long-term oxygen requires the guideline’s arterial-oxygen eligibility criteria and a documented assessment of falls, burns and fire risk. NICE does not offer it to people who continue smoking despite cessation support. [1]
- Do not offer long-term oxygen for isolated nocturnal hypoxaemia caused by COPD. When long-term oxygen is appropriately prescribed, advise at least 15 hours daily and review at least annually, including pulse oximetry. [1]
Assess severity and treat an acute deterioration
- An exacerbation is acute sustained worsening beyond usual day-to-day variation. Decide the care setting using breathlessness, general condition, ability to cope, consciousness, comorbidity, oxygenation and blood gases; severe deterioration or inability to cope favours hospital care. [1]
- For hospital presentations, obtain chest radiography, arterial blood gases with inspired oxygen documented, ECG, blood count and electrolytes. Culture purulent sputum and obtain blood cultures with fever; check theophylline levels if it is being taken. [1]
- Increase short-acting bronchodilator treatment as needed, using an inhaler or nebulizer suited to the person and required dose. If hypercapnic or acidotic, drive the nebulizer with compressed air; give any necessary oxygen separately by nasal cannula. [1]
- Unless significantly contraindicated, give oral corticosteroids for hospitalized exacerbations and consider them in community exacerbations causing increased breathlessness that disrupts daily activity. This NICE regimen is prednisolone 30 mg orally daily for 5 days; explain the stopping plan and adverse effects. [1]
- Use a separate antimicrobial-prescribing pathway for exacerbation antibiotics. Prescribe oxygen to an individualized target and repeat arterial gases according to response; pulse oximetry does not measure carbon dioxide or pH. [1]
- NIV is the treatment of choice for persistent hypercapnic ventilatory failure despite optimal treatment. Deliver it in an experienced dedicated service with an agreed deterioration plan and treatment ceiling. When considering invasive ventilation, do not use age or FEV1 in isolation. [1]
- Before discharge, restore optimal maintenance bronchodilators, confirm satisfactory oxygenation or blood gases after respiratory failure, explain medication and oxygen use, and arrange follow-up and home support. The person and carers should be confident they can manage. [1]
Limitations and use
- This is a selected NICE pathway, not a complete COPD reference. It omits detailed long-term oxygen pressure thresholds, prophylactic antibiotics, biologic or roflumilast eligibility, lung-volume reduction, transplant selection and palliative regimens.
- Do not combine the NICE steroid dose or inhaler escalation rules with another guideline without clearly identifying which source governs the decision. Current regional availability and individual contraindications remain relevant.
- The summary does not establish an emergency oxygen flow rate or universal saturation target. Blood gases, prior hypercapnic failure, monitoring and the relevant acute oxygen protocol are required.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Chronic obstructive pulmonary disease in over 16s: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 5 December 2018
- Publisher’s latest update
- 26 July 2019
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: chronic obstructive pulmonary disease nice
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.